<DOC>
	<DOCNO>NCT02120898</DOCNO>
	<brief_summary>The purpose study compare safety efficacy profile generic imiquimod 2.5 % cream reference list Zyclara速 ( imiquimod ) cream treatment actinic keratosis .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Imiquimod Cream , 2.5 % Subjects With Actinic Keratoses</brief_title>
	<detailed_description>Aldara速 ( imiquimod ) Cream , 5 % first imiquimod product approve FDA topical treatment actinic keratosis , superficial basal cell carcinoma external genital perianal wart . The FDA approve regimen treatment AK application 250 mg cream twice week 16 week 25-cm2 area . In 2011 , low strength imiquimod cream , Zyclara ( imiquimod ) Cream , 2.5 % approve FDA . When used treatment AK , Zyclara apply short duration expand treatment area ( e.g. , face scalp ) comparison Aldara速 . This study conduct compliance protocol , Good Clinical Practice ( GCP ) applicable regulatory requirement ( ) . Marketed Medicis , Zyclara速 ( imiquimod ) cream 2.5 % safe effective topical therapy treatment actinic keratosis face scalp . Actavis develop generic formulation imiquimod 2.5 % cream current study design evaluate safety efficacy formulation .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Subject male female , 18 year age old . Subject provide write informed consent . Subject willing able apply test article direct , comply study instruction commit followup visit duration study . Subject clinical diagnosis actinic keratoses ( AK ) least five ( 5 ) twenty ( 20 ) clinically typical , visible palpable AK lesion , least 4 mm diameter , area great 25 cm2 face ( exclude ear ) bald scalp , . Subject good general health free disease state physical condition might impair evaluation AK lesion , investigator 's opinion , expose subject unacceptable risk study participation . Females must postmenopausal1 , surgically sterile2 use effective method birth control3,4 negative urine pregnancy test ( UPT ) 5 Baseline Visit . Subject pregnant , lactating , plan become pregnant study . Subject hyperkeratotic , hypertrophic atypical AKs ( e.g. , AK &gt; 1 cm2 size ) treatment area . Subject currently enrol investigational drug device study . Subject plan expose artificial tanning device excessive sunlight trial . Subject immunosuppressed ( e.g. , HIV , systemic malignancy , graft vs. host disease , etc. ) . Subject experienced unsuccessful outcome previous imiquimod therapy ( unsuccessful outcome define reasonable therapeutic trial compliance issue topical drug work ) . Subject used investigational drug investigational device within 30 day prior Baseline Visit . Subject dermatologic procedure surgery : laser resurfacing , PUVA ( Psoralen + ultraviolet A ) therapy , UVB therapy , chemical peel dermabrasion face bald scalp within six ( 6 ) month prior Baseline Visit . Subject cryodestruction chemodestruction , curettage , photodynamic therapy , surgical excision treatment actinic keratosis designate treatment area ( face scalp ) within one month prior Baseline Visit . Subject use oral corticosteroid therapy , interferon , cytotoxic drug , immunomodulators , immunosuppressive therapy retinoids within one month prior Baseline Visit . Subject use topical medication ; corticosteroid , alpha hydroxyl acid ( e.g. , glycolic acid , lactic acid etc . &gt; 5 % ) , beta hydroxy acid ( salicylic acid &gt; 2 % ) , urea &gt; 5 % , 5fluorouracil , diclofenac , imiquimod , ingenol mebutate prescription retinoids ( e.g. , tazarotene , adapalene , tretinoin ) face bald scalp within one month prior Baseline Visit . Subject use topical cream , lotion gel kind select treatment area within one day prior Baseline Visit . Subject lesion suspicious skin cancer ( skin cancer rule biopsy ) untreated skin cancer within select treatment area ( face scalp ) . Subject history sensitivity ingredient test article ( see Section 6.1 ) . Subject skin pathology condition ( e.g. , facial/scalp psoriasis , atopic dermatitis , acne , rosacea , etc . ) , investigator 's opinion , could interfere evaluation test article , worsen due treatment require use interfere topical , systemic surgical therapy . Subject condition , investigator 's opinion , would make unsafe precludes subject 's ability fully participate research study . Subject know noncompliant unlikely comply requirement study protocol ( e.g. , due alcoholism , drug dependency , mental incapacity ) opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>Imiquimod</keyword>
	<keyword>Zyclara</keyword>
</DOC>